SOURCE: Crucell N.V.

November 13, 2006 10:47 ET

Invitation Conference Call Analyst Meeting

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- November 13, 2006 --

During its Analyst Meeting on November 16 in New York Crucell will organize a conference call for those analysts who are unable to attend the meeting in person and who would like to ask questions during the audio webcast.

                   Thursday, 16 November, 2006 at
                        8.30 US Eastern Time
                     14.30 Central European Time

          Please call one of one of the following numbers:
      1-888-408-5406 (toll-free) or +1-480-293-1748 for the US,
      0800-358-5255(toll-free) or +44-20-7190-1492 for the UK,
   0800-265-8529(toll-free) or +31.20.794.8507 for the Netherlands
                  10 minutes prior to commencement
Following the presentations you will be able to ask questions during the questions and answers session.

Presentation slides will be available on the investor relations section of Crucell's website at: There will be an audio webcast of the conference call, which will be archived and available for replay following the event.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information

  • For further information please contact:

    Crucell N.V.
    Paul Vermeij
    Director Investor Relations and Corporate Communications
    Tel. +31-(0)71-524 8718
    Email Contact

    For Crucell in the US:
    Redington, Inc.
    Thomas Redington
    Tel. +1 212-926-1733
    Email Contact